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Abstract Silver nanoparticles (Ag NPs) are increasingly 
used in biomedical applications because of their large 
antimicrobial spectrum. Data in the literature on the 
ability of Ag NPs to perform their desired function 
without eliciting undesirable effects on blood elements 
are very limited and contradictory. We studied the 
impact of Ag NPs on erythrocyte integrity, platelet 
function and blood coagulation. Erythrocyte integrity was 
assessed by spectrophotometric measurement of 
haemoglobin release. Platelet adhesion and aggregation 
was determined by light transmission aggregometry and 
scanning electron microscopy. The calibrated thrombin 
generation test was used to study the impact on 
coagulation cascade. We demonstrated that Ag NPs 
induced haemolysis. They also increase platelet adhesion 
without having any impact on platelet aggregation. 
Finally, they also had procoagulant potential. Bringing all 
data from these tests together, the no observed effect 
concentration is 5 µg/mL. 
 





Silver has been used in medicine for centuries on account 
of its antimicrobial properties [1, 2]. Because of their large 
surface area-to-volume ratios, silver nanoparticles (Ag 
NPs) offer a large antimicrobial spectrum and greater 
efficacy against bacteria than common antibiotics [3-5]. 
Ag NPs provide new opportunities for use in both 
consumer and biomedical applications, making them the 
most commercialised NPs [6]. For example, they are 
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integrated into garments in order to neutralize odour-
forming bacteria [7], they coat various food contact 
materials (refrigerator surfaces, storage bags…) on 
purpose to inhibit microorganism growth and to preserve 
food longer [8]. They are also used in disinfectants, 
deodorants, water purificants, antimicrobial sprays, etc. 
[9]. In the medical field, Ag NPs coat cardiovascular and 
neurosurgical catheters, orthopaedic and cardiovascular 
implants, surgical instruments, wound and burn 
dressings, and bone substitute biomaterials [1, 3, 10, 11]. 
Other biomedical applications of Ag NPs include drug 
delivery systems and targeting [12]. Moreover, Ag NPs 
have demonstrated anti-inflammatory effects, improving 
the outcome of the healing process [13, 14].  
 
In some biomedical applications, Ag NPs are directly in 
contact with blood. Because of their reduced particle size 
and increased surface area Ag NPs may also enter the 
body and translocate into systemic blood flow after 
inhalation, ingestion, dermal contact or systemic 
administration [9, 15-17]. Ag NPs, after inhalation, oral 
administration or subcutaneous injection in rats, may 
reach the blood stream and be distributed to organs 
including liver, kidney and brain [15-19]. Information on 
the potential impact of Ag NPs on haemolysis, platelet 
activity and coagulation associated with human exposure 
is however very limited [3, 10]. An important haemolysis 
(destruction of red blood cells (RBC)) may result in 
pathological conditions such as anaemia and renal failure 
[20]. Moreover, a homeostatic imbalance in platelet 
function (primary haemostasis) or in the coagulation 
system (secondary haemostasis) can lead to thrombotic or 
haemorrhagic disorders. The plasma coagulation cascade, 
responsible for blood clotting, consists in a series of 
sequential enzymatic reactions performed by activated 
coagulation factors. It can be triggered through two 
distinct pathways: the cell-mediated tissue factor (TF) 
pathway and the surface-mediated contact pathway 
(formerly known as extrinsic and intrinsic pathways, 
respectively). Both pathways converge to a common 
pathway resulting in active thrombin generation and 
fibrin clot formation. The majority of these proteolytic 
reactions occur on anionic phospholipid membrane 
surfaces from activated platelets or endothelial cells in
vivo and require calcium as a cofactor [21]. There is 
therefore a plausible possibility that some nanomaterials 
interfere with some of these reactions, as recently 
demonstrated [22]. In the present study, we focused on 
the effects of Ag NPs on three parameters of blood: (i) 
haemolysis, (ii) primary haemostasis and (iii) secondary 
haemostasis.  
 
It is proposed that the no observed effect concentration 
(NOEC) identified for a particular NP in the most 
sensitive in vitro assay of the haemocompatibility testing 
battery could be used to guide the selection of the human 
free plasma concentration that could be considered safe 
from a haemocompatibility perspective for a first-in-
human exposure, and to identify appropriate safety 
margins (i.e., the ratio between the NOEC and the human 
free plasma concentration at the clinical starting dose). In 
addition, the lowest effect concentration (LOEC) for a 
particular NP could similarly be extrapolated to estimate 
the human plasma concentration where haematotoxicity 
would be expected to occur (toxic concentration). Both 




2.1 Nanoparticle characterization 
 
Ag NPs were obtained from the European project 
NanoValid. They were suspended in water at a stock 
concentration of 40 mg/mL, stabilized by polyvinyl 
pyrolidone (PVP) and stored at 4°C. Ag NPs were diluted 
in tyrode buffer (10 mM Hepes, 6 mM NaHCO3, 137 mM 
NaCl, 2.7 mM KCl, 5 mM glucose, 1 mM MgCl2 and 0.8 
mM NaH2PO4, diluted in ultrapure water (milliQ 18.2 
MW.cm), pH 7.4).  
 
A proper characterization of Ag NPs was performed as 
previously reported [23]. Briefly, the bulk composition was 
determined by energy dispersive X-ray (EDX). The surface 
composition was analysed with an X-ray photoelectron 
spectroscopy (XPS) system. A droplet of 10 µL of the Ag 
NPs dispersion was left to dry on a gold-covered silicon 
wafer. The particle size distribution was measured with a 
DC24000 system Disc Centrifuge (CPS Instruments Inc.). A 
certified PVC microparticle calibration standard (226 nm), 
provided by the instrument supplier, was used to calibrate 
all measurements. The volume injected was 0.02 mL for 
each experiment.  
 
2.2 Preparation of human platelet-rich plasma (PRP),  
platelet-poor plasma (PPP) and washed red blood cells  
(RBC) suspension and normal pooled plasma (NPP) 
 
PRP, PPP, whole blood, washed RBC suspension and 
NPP were prepared with blood from healthy volunteers 
who were free from any medication for at least two 
weeks. Blood was collected by venepuncture into tubes 
containing buffered sodium citrate (109 mM, nine parts 
blood to one part of sodium citrate solution) (BD 
Vacutainer®). The study protocol was in accordance with 
the Declaration of Helsinki and was approved by the 
Medical Ethical Committee of the CHU Dinant-Godinne 
UCL Namur (Yvoir, Belgium). 
 
Platelet-rich plasma (PRP) was carefully prepared by 
centrifugation at 200 g at room temperature for 10 min. 
The platelet count was adjusted to 300,000 platelets/µL 
and PRP were used immediately after preparation. 
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Platelet-poor plasma (PPP) was subsequently obtained by 
centrifugation at 2,000 g of the pellet at room temperature 
for 10 min. It was frozen at -80 °C immediately after 
centrifugation. It was defrosted at 37 °C just before use. 
 
To prepare a suspension of washed RBC in PBS, whole 
blood is centrifuged at 3,000 g over 5 min. The PPP is 
removed and used for interference assays. RBC are washed 
with physiological phosphate buffered saline (PBS, 6.7 mM 
phosphate, pH=7.4) three times with intermediate 
centrifugation of 3,000 g over 5 min. They are then 
resuspended in PBS with the same volume as PBS removed.  
 
For NPP, a total of 40 healthy individuals were included in 
the study. The exclusion criteria were thrombotic and/or 
haemorrhagic events, antiplatelet and/or anticoagulant 
medication, pregnancy and uptake of drugs potentially 
affecting the platelet and/or coagulation factor functions 
during the two weeks prior to the blood drawn. A written 
informed consent was obtained from each donor. The 
study population displayed the following characteristics: 
24 females and 16 males aged from 19 to 48 years (mean 
age = 25 years) with body mass index (BMI) ranging from 
16.8 to 34.6 kg/m2 (mean BMI = 22.3 kg/m2). After collection 
of blood, the PPP was obtained from the supernatant 
fraction of the blood tubes after a double centrifugation for 
15 minutes at 2,000 g at room temperature. It was 
immediately frozen at –80°C after centrifugation. The NPP 
samples were thawed and kept at 37 °C just before use. 
 
2.3 Haemolysis assays 
 
Haemolysis assays were performed on the blood of one 
healthy donor: 15 µL of nanoparticles (suspended in 
tyrode), tyrode (negative control) or triton X-100 (positive 
control) are added to 285 µL of whole blood (protocol 1) 
or washed RBC (protocol 2). The suspension is incubated 
at room temperature on a shaking plate during 1 h, 4 h 
and 24 h. After the incubation time, the suspension is 
centrifuged at 10 000 g over 5 min. Supernatant is read in a 
96-well plate using a microplate scanning 
spectrophotometer XMark (Biorad, USA) at 550 nm. The % 
haemolysis was calculated as: H (%) = (OD550nm sample – 
OD550nm tyrode)/(OD550nm Triton X-100 1% - OD550nm 
tyrode)*100. For each term of the equation, the 
corresponding interference was subtracted. The 
interference corresponds to the same conditions except that 
the solution does not contain RBC. Positive and negative 
controls induced 100% and 0% of lysis, respectively. The 
results were expressed as means ± SD (n = 3).  
 
2.4 Platelet functional assays 
2.4.1 Light transmission aggregometry (LTA)  
The impact of Ag NPs on spontaneous or induced platelet 
aggregation was studied using the chronometric 
aggregometer type 490-2D as previously reported [24]. 
The reaction mixture for spontaneous aggregation tests 
contained 285 µL of PRP at 300,000 platelets/µL and 15 
µL of NPs with final concentrations from 1 to 25 µg/mL. 
The reaction mixture for induced aggregation tests 
contained 255, 255 or 280 µL of PRP at 300,000 
platelets/µL, with respectively 30 µL of ADP (final 
concentration: 20 µM, Bio/Data corporation, USA), 30 µL 
of collagen (final concentration: 190 µg/mL, calf skin, 
Bio/Data corporation, USA) or 6 µL of arachidonic acid 
(AA, final concentration: 600 µM, Calbiochem, Germany) 
and 15 µl of NPs at final concentration from 1 to 25 
µg/mL. Inducers alone were also used before any 
experiment to check platelet reactivity. PPP was used as a 
reference. Data were collected with the chronolog two-
channel recorders at 405 nm connected to a computer. 
 
2.4.2 Scanning electron microscopy (FEG-SEM) 
 
Preparation of samples was similar to LTA. The samples 
of PRP (500 µL) were deposited on a glass slice coated 
with poly-L-lysine; 500 µL of glutaraldehyde (final 
concentration: 2.5%) in cacodylate buffer 
(Na(CH3)2.AsO2.3H2O in distilled water at pH 7.4, final 
concentration: 0.1 M) was added over 90 minutes. 
Samples were then centrifuged at 2,000 g for platelet 
adhesion onto the slice. The glutaraldehyde solution was 
removed and 400 µL of 0.2 M cacodylate buffer was 
added. The next step is the dehydration of the sample 
with successive baths of alcohol from 30° to 100°. A 
critical point drying was performed with a specific 
apparatus: the Balzers Critical Point Dryer (CPD) 030 
(BAL-TEC GmbH®, Germany). Afterwards, a thin layer of 
platinum (20 nm) was deposited under argon atmosphere 
on the sample with the metallizer Balzers union (BAL-
TEC GmbH®, Germany). The samples were observed 
with FEG-SEM (Jeol, Japan; resolution of 0.6 nm at 20 
keV) [22].  
 
2.5 Coagulation: Calibrated thrombin generation test (cTGT) 
 
The impact of Ag NPs on coagulation was studied using 
the calibrated thrombin generation test (cTGT) as 
previously reported [22]. For each experiment, a fresh 
mixture of fluorogenic substrate/calcium chloride 
buffered solution was prepared as follows: 2.6 mL of Fluo 
Buffer® (Thrombinoscope BV, The Netherlands) were 
mixed with 65 µL of Fluo substrate® (100 mM in DMSO, 
Thrombinoscope BV, The Netherlands). PPP-Reagent, 
PPP-Reagent LOW, MP-Reagent and Thrombin 
Calibrator (Thrombinoscope BV, The Netherlands) are 
four inducers, giving final assay concentrations of 5 pM 
tissue factor (TF) with 4 µM phospholipids (PL) and 16.7 
mM CaCl2; 1 pM TF with 4 µM PL and 16.7 mM CaCl2; 4 
µM PL and 16.7 mM CaCl2; and 620 nM α2-
macroglobulin-thrombin complex, respectively. They are 
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reconstituted with 1 mL distilled water according to the 
instructions provided by the manufacturer. A calibration 
curve was simultaneously performed using the thrombin 
calibrator. The acquired data were automatically 
processed by the software, which provided thrombin 
activity curves and lag time (minutes), Cmax (nM) and 
endogenous thrombin potential (ETP, nM*minutes) 
parameters. The NP suspensions were tested at final 
concentrations from 5 to 500 µg/mL. Statistical analyses 
were conducted with an unpaired t-test using the 
GraphPad Prism software (GraphPad software, v 5.01, 
USA).  
2.6 Interferences of NPs with the detection methods used  
2.6.1 NP interferences with methods using  
light absorbance detection  
Haemolysis assay and LTA use light absorbance detection. 
In order to study light interference of NPs, 20 µL of Ag NP 
suspensions and 180 µL of suspension agent were mixed in 
a 96-well polystyrene plate (Greiner Bio One, Belgium). 
The light absorbance was measured from 400 to 800 nm 
using a microplate absorbance spectrophotometer XMark 
(Biorad, USA). For haemolysis assay, the interference was 
avoided by the subtraction of the OD550nm of NPs 
suspended in the vehicle from the measured OD550nm at the 
same concentration. For LTA, the NP concentration 
requiring an increase of 0.1 unit of the OD at 405 nm (Δ0.1 
OD405nm) was calculated from the plot of the OD405nm against 
the NP concentration by a linear regression curve using the 
GraphPad Prism® software (GraphPad Prism software, v 
5.01, USA). The lower this parameter, the more NP 
suspensions absorb light.  
 
2.6.2 NP interferences with the cTGT method  
 
The autofluorescence of the NP suspensions was 
measured at 390/460 nm using the microplate fluorometer 
Fluoroskan Ascent® FL (Thermo Labsystems, The 
Netherlands). Furthermore, the quenching of 7-amino-4-
methyl coumarin acetic acid (AMC) by the NP 




3.1 Nanoparticle characterization 
 
Ag NPS have a spheroid shape.  
 
A bimodal distribution was observed with primary 
particles around 16 nm and agglomerates around 71 nm 
(Table 1). The NP surface composition was not similar to 
their bulk composition with a lower content of oxygen 
and the presence of nitrogen. The elements other than Ag 




16 (primary particles),  
71 (agglomerates) 
Elemental composition Ag O C N Na 
Surface composition  
(XPS, [% at])* 
5 23.8 61 9.2 1 
Bulk composition  
(SEM-EDX, [% at])* 
4.71 34.22 60.78 -- 0.29 
* Ag NPs are dispersed in water and stabilized with PVP 




We performed the absorbance spectrum of the 
supernatant of RBC suspension 0.5% (v/v) incubated with 
Triton X-100 1% (v/v) (data not shown). We selected the 
wavelength of 550 nm to perform our assay. Note that 
OD interference has been observed with Ag NPs due to 
their absorbance at 550 nm. This interference was avoided 
by the subtraction of the OD550 nm of NPs suspended in the 
vehicle from the measured OD550 nm at the same 
concentration. Negative control (tyrode) and positive 
control (triton X-100 1%) induced 0% and 100% 































Figure 1. Human RBC lysis (%) induced by Ag NPs in washed 
RBC after 1 h, 4 h and 24 h at concentrations ranging from 1 to 
100 µg/mL (protocol 2). Triton X-100 1% and tyrode (v/v) are 
respectively used as positive control and negative control. Mean 
(%) ± SD, n = 3. Statistical analysis was performed with 
GraphPad Prism software (unpaired t-test). Statistical 
significance between control and Ag NPs samples: * indicates 
p<0.05.  
 
Ag NPs at 1 µg/mL, 10 µg/mL and 100 µg/mL induced no 
haemolysis in whole blood (data not shown) after 1 h, 4 h 
or 24 h (data not shown). With washed RBC, no 
haemolysis was observed, except for the concentration of 
100 µg/mL after 24 h of incubation. A statistically 
different percentage of haemolysis (4.7%) is obtained 
(Figure 1).  
 
3.3 Platelet function 
 
To evaluate the suitability of LTA for Ag NPs, the light 
absorbance properties of these NPs was determined. Ag 
NP suspensions absorb light between 400 and 800 nm. 



























































































































Figure 2. Platelet aggregation induced by ADP (A), collagen (B) 
or AA (C) at different concentrations of Ag NPs. PBS is used as a 
negative control. Results are expressed as % of response (Mean ± 
SD, n = 6, unpaired t-test). 
 
According to the detection sensitivity of LTA, the NP 
concentration required to obtain a 0.1 unit increase in the 
OD at 620 nm (Δ0.1 OD620 nm) was measured; significant 
light absorbance was observed from a concentration 
higher than 10 µg/mL Ag NPs.
 
The potential impact of Ag NPs on platelet activity was 
investigated at the concentration without interference in 
tested conditions (< 25 µg/mL). The cut-off was arbitrarily 
defined at 5% reduction of the aggregation by agonist in 
control conditions. At the investigated concentrations 
avoiding interferences, Ag NPs did not significantly 
affect platelet aggregation, regardless of the inducer used 
(ADP, collagen or AA) (Figure 2). In the absence of 
agonists, Ag NPs did not induce spontaneous platelet 
aggregation (data not shown). 
 
In FEG-SEM, a reduction of platelet adhesion is observed 
with Ag NPs at 50 µg/mL (Figure 3 D and E). FEG-SEM 
does not allow conclusion of a potential effect of Ag NPs 
on the platelet activation and aggregation (Figure 3).  
 
 
Figure 3. SEM pictures of platelet adhesion without (A -C) or 
with Ag NPs at a final concentration of 50 µg/mL (D -F). Platelet 
aggregation was induced by AA (C,F). Scale bare = 10 µm (A, D) 
or 1 µm (B, C, E, F). Arrows indicate adherent platelets. 
 
3.4 Coagulation: Calibrated thrombin generation test (cTGT) 
The investigations of the two potential interferences of 
Ag NPs with cTGT indicated that Ag NPs were not 
autofluorescent at wavelengths of 390/460 nm, but they 
were able to reduce the fluorescent signal of the AMC 
fluorophore. This interference can be excluded by 
performing a specific calibration curve for each 
concentration tested [22].  
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Figure 4. Representative thrombin activity profiles induced by 
TF (A), contact (C) or both pathways (B) in the presence of Ag 
NPs. Data shown are the means of three independent 
experiments.  
 
Figure 4 shows representative active thrombin profiles 
after activation by the use of three specific inducers in the 
presence of Ag NPs. Figure 5 represents the control 
parameters. Firstly, the investigation of the TF pathway 
showed that only a high concentration of Ag NPs (500 
µg/mL) increases the concentration of generated 
thrombin (Cmax) (Figure 4A and Figure 5B). Secondly, the 
active thrombin was generated through the TF pathway, 
but with a lower concentration of TF in order to allow the 
thrombin-positive feedback loop activation on the contact 
pathway (Figure 4B). In these specific activation 
conditions, it appeared that high concentration decreased 















































































































Figure 5. Control parameters (lag time (A), Cmax (B) and ETP (C)) 
of thrombin activity profiles induced by TF, contact or both 
pathways of negative control and different concentrations of Ag 
NPs. Statistical analysis was performed with GraphPad Prism 
software (unpaired t-test). Statistical significance between control 
and Ag NPs samples: * indicates p<0.05; ** indicates p<0.01; *** 
indicates p<0.001.  
 
When the contact pathway was triggered, Ag NPs 
showed a procoagulant activity with a decrease of lag 
time and an increase of Cmax (Figure 4C). Based on these 
results, it appears that Ag NPs have a procoagulant 
activity by reducing lag time and by increasing Cmax when 
the contact pathway (4 µM PL) is preferentially 
stimulated.  
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3.5 No/low observed effect concentration 
 
NOEC and LOEC were determined for blood parameters 
studied. For red blood cells, the NOEC and LOEC were 
50 µg/mL and 100 µg/mL, respectively. The NOEC and 
LOEC were 5 µg/mL and 50 µg/mL for coagulation, 
respectively. For platelet function, due to the technical 
limitations of LTA, the NOEC is 25 µg/mL and no LOEC 
could be determined. The effects on platelet adhesion 
observed in FEG-SEM are a qualitative result allowing no 




The increasing use of Ag NPs leads to the need of 
toxicological evaluation to insure patient safety [25]. 
There is limited information on the biological effects of 
Ag NPs on human blood cells and the potential risk of 
inducing thrombosis [11]. Moreover, some published 
studies do not provide information on interferences of the 
assays. In addition, results are sometimes contradictory 
[26-29]. Physicochemical properties of NPs are of major 
importance in toxicology and may be affected by the 
dispersing media [30, 31]. Therefore, results of blood 
assays can differ according to the media used. We 
suggested that the NP suspensions should be prepared in 
the most physiological media suitable for blood 
components (tyrode buffer), avoiding sonication [22, 25]. 
As their unique size and composition affect their 
functionality, complete physicochemical description of 
nanoparticles was performed, allowing the comparison of 
results between scientific studies [25].  
 
The determination of haemolysis is based on 
haemoglobin absorbance at 550 nm, with subtraction of 
the interference of Ag NPs. A significant difference was 
observed in washed RBC with Ag NPs at 50 and 100 
µg/mL after 24 h of incubation in comparison with 
controls. A lower haemolytic effect was observed in 
whole blood than in washed RBC. This is probably due to 
the fact that, in whole blood, an adsorption of plasma 
proteins on the NPs may occur and impact upon the 
haemolytic properties. This effect has already been 
reported in the literature for SiO2 NPs [32, 33]. Although 
various studies evaluated the haemolysis induced by Ag 
NPs [25, 34, 35], it remains difficult to compare results 
across studies due to the lack of harmonization of 
standardized physicochemical characterizations and in
vitro haemolysis protocols. However, our results are in 
agreement with previous studies that concluded to the 
prohaemolytic properties of Ag NPs [25, 34, 35]. These 
results may have a clinical impact, since a release of 
haemoglobin can lead to adverse health effects such as 
anaemia, pulmonary hypertension, renal toxicity [36]. 
The mechanism explaining this induced haemolysis by 
Ag NPs has not yet been completely elucidated. It is 
known that low concentrations of Ag ions lead to RBC 
death [37, 38]. In contact with blood, metallic silver 
ionizes and releases ions in the bloodstream, which can 
interact with transmembrane proteins [2, 25]. However 
silver ion generation is not the only factor for haemolysis; 
other mechanisms contribute to haemolysis induced by 
NPs (deformability, adhesiveness, membrane 
vesiculation etc.) [25, 39].  
 
Two techniques were used to assess the potential effect of 
Ag NPs on platelet function: LTA and FEG-SEM. With 
the first technique, Ag NPs did not affect the platelet 
aggregation at the highest tested concentration avoiding 
interferences (25 µg/mL). Jun et al. also showed 
interference of Ag NPs with light transmission, especially 
at high concentrations. With the second technique, an 
increase of the platelet adhesion is observed at 50 µg/mL, 
with no observed effect on the two following steps of the 
primary haemostasis (i.e., platelet activation and 
aggregation). Jun et al. and Krajewski et al. demonstrated 
that Ag NPs induce platelet activation and aggregation 
[26, 27]. An anti-aggregating effect of Ag NPs has been 
demonstrated by Shrivastava et al. using LTA [40]. 
However, the interference of Ag NPs was not taken into 
account with this technique. Moreover, as discussed by 
Deb et al., the anti-platelet effect observed by Shrivastava 
et al. was due to citric acid present at the surface of the 
NPs [41]. The key mechanism underlying platelet 
activation induced by Ag NPs would be an increase of 
intracellular calcium levels, directly related to GPIIb/IIIa 
activation and leading to P-selectin expression and 
serotonin secretion [26]. 
 
On coagulation, the sensitive cTGT assay showed that Ag 
NPs had significant procoagulant activity. These results 
were in accordance with the work of Jun et al. which 
demonstrated the procoagulant activity of silver NPs 
<100 nm on two different assays (chromogenic generation 
assay and P-selectin expression) [26]. In the cTGT assays, 
the interferences (autofluorescence of the NP suspensions 
and the quenching of the fluorophore signal) are 
excluded by performing, for each NP concentration, a 
specific calibration curve run [22]. To explain the 
procoagulant effect observed, Jun et al. suggested that Ag 
NPs enhance procoagulant activity through 
phosphatidylserine exposure in platelets [26]. On the 
other side, Shrivastava et al. concluded to a delay of fibrin 
polymerization by silver NPs (10-15 nm). Interestingly, 
this effect is strongly inhibited when the experiment is 
performed with bovine serum albumin at a concentration 
below the protein concentration in the blood [28]. 
Martínez-Gutierrez et al. concluded to a moderate 
anticoagulant effect of Ag NPs on the intrinsic pathway 
performing an activated partial thromboplastin time 
(aPTT). We performed the same assay using a mechanical 
semi-automated coagulometer KC10 (Amelung, 
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Germany) with Synthasil® (Instrumentation Laboratory, 
Lexington, KY, USA) and CK Prest® (Diagnostica Stago, 
Asnières, France). We observed a significant and dose-
dependant decrease in coagulation with aPTT with Ag 
NPs (data not shown). Contrarily, we demonstrated a 
procoagulant effect of Ag NPs with cTGT mainly on the 
contact pathway. The conclusion of a procoagulant 
activity performed by cTGT should be regarded as more 
physiologically relevant and predictive. Indeed, reagents 
used in KC 10 contain, in addition to phospholipid 
substitutes, colloidal silica activator for Synthasil® and 
kaolin for CK Prest® to induce the contact pathway. cTGT 
reagents contain physiological phospholipids. In KC10, 
an interaction of charges between the negatively charged 
reagents and the Ag NPs delivering positive ions is 
anticipated. Consequently, this non-physiological 
interaction prevents tenase and prothrombinase complex 
formation, finally inducing an increase in the coagulation 
time. Moreover, procoagulant activity mediated by 
platelets could amplify the procoagulant effect observed 
on the coagulation cascade by Ag NPs. Because of the 
abovementioned interactions, aPTT using colloidal silica 
activator or kaolin to induce the contact pathway should 
not be considered as a relevant assay for assessing the 
impact of charged nanomaterials on coagulation. As 
suggested in previous work, cTGT appears to be the gold-
standard assay [22]. 
 
Regarding biomedical applications, Ag NPs are currently 
used for wound dressing because of their antimicrobial 
effect [42]. Moreover, recent studies have shown that Ag 
NPs have significant anti-inflammatory effects [13, 43], 
preventing the wound from inflammation. In this study, 
we demonstrated a platelet proadhesion and a 
procoagulant effect promoting the healing process [44]. 
 
In the emerging field of nanomedicine, blood could be in 
contact with Ag NPs after injection or direct contact 
(coated biomaterial). We demonstrated prohaemolytic, 
proadherent and procoagulant effects of Ag NPs that 
could enhance the risk of thrombosis.  
 
The most sensitive in vitro assay of the 
haemocompatibility testing battery for Ag NPs is the 
cTGT, used to propose a NOEC at 5 µg/mL and a LOEC 
at 50 µg/mL. The NOEC could be used to determine a 
safe human plasma-free concentration for a first-in-
human exposure and to identify appropriate safety 
margins. In addition, the LOEC could estimate the human 
plasma concentration where haematotoxicity would be 
expected to occur. As the human maximum therapeutic 
free plasma concentration would approach the toxic 
concentration, the probability of toxicity would increase 
and the exposure margin would decrease. The latter 
could also guide specific safety monitoring that would 
need to be foreseen in a clinical setting. As such, these in
vitro hemocompatiblity data could contribute to the 
identification of starting and maximum doses as 
described in the ICH M3(R2) guideline on non-clinical 
safety studies for the conduct of human clinical trials and 
marketing authorization for pharmaceuticals [45]. It 
should be noted that the use of in vitro (haemato-) toxicity 
data in a decision-making process could be considered 
provided that the basic criteria of test method 




Silver NPs present numerous interactions with blood 
components as RBCs, platelets and a coagulation system. 
We recommend specific haematological tests overcoming 
interferences to determine NP haemocompatibility and 
estimate NOEC. Using such tests, Ag NPs demonstrated 
prohaemolytic, procoagulant effects, and promote platelet 
adhesion. A maximal NOEC and LOEC in blood have 
been determined at 5 and 50 µg/mL, respectively. For 
local Ag NPs applications such as wound dressings, these 
properties may be favourable. For the development of Ag 
nanomedicines from a haemocompatibility perspective, 
the NOEC and LOEC may be useful for first-in-human 
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